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We have identified the tRNAs which are incorporated into both wild-type human immunodeficiency virus
type 1 strain HIB (HIV-111,B) produced in COS-7 cells transfected with HlV-1 proviral DNA and mutant,
noninfectious HIV-1L, particles produced in a genetically engineered Vero cell line. The mutant proviral DNA
contains nucleotides 678 to 8944; i.e., both long terminal repeats and the primer binding site are absent. As
analyzed by two-dimensional polyacrylamide gel electrophoresis, both mutant and wild-type HIV-1 contain
four major-abundance tRNA species, which include tRNALYS, tRNAI"Y (the putative primer for HIV-1 reverse
transcriptase) and tRNA". Identification was accomplished by comparing the electrophoretic mobilities and
RNase T, digests with those of tRNA3LY' and tRNAj', purified from human placenta and comparing the partial
nucleotide sequence at the 3' end of each viral tRNA species with published tRNA sequences. Thus, the absence
of the primer binding site in the mutant virus does not affect tRNALYS incorporation into HIV-1. However, only
the wild-type virus contains tRNALY" tightly associated with the viral RNA genome. The identification of the
tightly associated tRNA as tRNA3LY' is based upon an electrophoretic mobility identical to that of tRNALYS and
the ability of this RNA to hybridize with a tRNALys-specific DNA probe. In addition to the four wild-type tRNA
species, the mutant HIV-1-like particle contains two tRNAH'S species and three tRNA-sized species that we have
been unable to identify. Their absence in wild-type virus makes it unlikely that they are required for viral
infectivity.
In the early stages of viral infection, the conversion of the
retroviral RNA genome into DNA which can be integrated
into the infected host cell genome is catalyzed by a virus-
specific protein, reverse transcriptase (RT). This enzyme
requires a primer for activity, which in retroviruses is a
tRNA (9, 10, 12, 15, 20, 21, 29, 33, 36, 37). The 3'-terminal
18 nucleotides of primer tRNA bind to a complementary
region just 3' of the 5'-U5 region, which is termed the primer
binding site. In addition, recent evidence has indicated that
six to seven nucleotides within the 5'-U5 region may also
bind to a corresponding number of nucleotides in the TIC
loop (2) and that genomic RNA sequences 3' of the primer
binding site may play a role in facilitating primer tRNA
binding to the RNA genome (21). The sequence of the primer
binding site in human immunodeficiency virus type 1
(HIV-1) DNA suggests that the primer tRNA in this virus is
tRNA3 ys (30), one of the three major tRNALYS isoacceptors
in mammalian cells (29). Purified bovine tRNA3YS has also
been shown to have the ability to interact with HIV-1 RT and
prime reverse transcription in vitro (3, 34). In this report, we
show that this tRNA is one of a few select tRNAs incorpo-
rated into HIV-1 during viral assembly.
The primer tRNA is selected for incorporation into the
virus from over 100 different host cell tRNA species. The
mechanism by which this occurs is largely unknown, and it
is not clear whether other tRNAs found in retroviruses are
also incorporated by the same mechanism. The number of
abundant tRNA-sized RNA species reported to be found in
retroviruses is quite variable, ranging from more than 20 (9,
11, 14, 26, 33) to only 2 (27). Even for a single-type virus,
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HIV-1, we have found that the number of major-abundance
tRNAs incorporated ranges from 4 to 25, depending upon the
cell type producing the virus (18). HIV-1 produced from
transfected COS cells contains only four major tRNAs (18)
and has been shown to be infectious (1, 31). The infectivity
of the virus produced by the particular HIV-1 proviral DNA
vector and COS-7 cell line used in this work has been
documented previously (13, 42). Since this virus contains
only four major-abundance tRNA species, the greater com-
plexity of the tRNA population seen in HIV-1 produced in
other cell types may not reflect the actual tRNA require-
ments for the viral life cycle. Are the tRNAs in COS
cell-produced virus selected because of unique functions
that they perform in the virus life cycle, or are these tRNAs
incorporated into the virus because of common structural
properties recognized by the selection mechanism, irrespec-
tive of having a viral function? The results in this report
indicate that the tRNAs incorporated probably share com-
mon structural properties, since in the COS-7 cell-produced
virions, the most abundant tRNAs incorporated are the
major tRNALYS isoacceptors. One of these, tRNALYS, be-
haves as a primer tRNA; i.e., it is the major viral tRNA
species found tightly associated with the viral genome.
Is primer tRNA first placed onto the primer binding site
and then carried into the virus with the genomic RNA, or is
it packaged independently of genomic RNA? It has been
observed that in defective murine leukemia virus (23) and
avian sarcoma virus (SE21Q1 [28]) lacking genomic RNA,
the patterns of tRNA incorporated match those of the
wild-type virus. In this work, we have examined the ability
of an HIV-1 mutant lacking the primer binding site (as well
as both long terminal repeats) to incorporate the normal
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pattern of tRNAs, including primer tRNA"Ys, and show that
select tRNA incorporation in HIV-1 does not depend upon
the presence of the primer binding site.
MATERIALS AND METHODS
Virus. HIV-1 produced in COS-7 cells was obtained by
transfecting these cells with HIV-1IIIB proviral DNA as
previously described (18). Virus was isolated from the su-
pernatant 63 h posttransfection. The supernatant was first
centrifuged in a Sorvall SS-34 rotor at 3,000 rpm for 30 min,
and the virus was then pelleted from the resulting superna-
tant by centrifugation in a Beckman Ti45 rotor at 35,000 rpm
for 1 h. The viral pellet was then purified by centrifugation at
26,500 rpm for 1 h through 15% sucrose onto a 65% sucrose
cushion, using a Beckman SW41 rotor.
The construction of plasmid pMT-HIV and the establish-
ment and characterization of a stable Vero monkey cell line
expressing the mutant virus have been described elsewhere
(16). Briefly, a proviral fragment from HIV-1_.i containing
only protein-coding information (nucleotides 678 to 8944)
was expressed in monkey kidney Vero cells by using the
inducible human metallothionein promoter. Noninfectious
HIV-like particles were secreted into the culture superna-
tant. These mutant virions contained all of the HIV-1 struc-
tural proteins and were purified by sucrose cushion centrif-
ugation.
Viral RNA isolation and fractionation. Total viral RNA was
extracted from viral pellets by the guanidinium isothiocy-
anate procedure (5). Total viral RNA containing both high-
molecular-weight genomic RNA and low-molecular-weight
tRNA was fractionated by using commercial Nucleobond
AX-20 columns (Nest Group, Southboro, Mass.). This col-
umn binds total viral RNA in a low-salt buffer (0.2 M KCl,
15% ethanol [EtOH], 100 mM Tris-P04 [pH 6.3]). Low- and
high-molecular-weight RNAs are eluted sequentially with
higher-salt buffers (18). tRNA is eluted with a 0.8 M KCl
buffer (0.8 M KCl, 15% EtOH, 100 mM Tris-P04 [pH 6.3]),
while genomic RNA and any tRNA associated with it are
eluted next, using a 1.3 M KCl buffer (1.3 M KCl, 15%
EtOH, 100 mM Tris-PO4 [pH 6.3]). The fractionation of free
and total associated tRNA was done as follows. An AX-20
column was equilibrated with 1 ml of 0.2 M KCl buffer.
Solutions were passed through the column by gravity.
Twenty micrograms of total viral RNA was dissolved in 500
,ul of 0.2 M KCI buffer and loaded on the column. The
column was then sequentially washed, first with 2 ml of 0.8
M KCI buffer, which elutes free viral tRNA, and then with 2
ml of 1.3 M KCI buffer, which elutes viral genomic RNA and
the tRNA associated with it, termed total associated tRNA.
Each 2-ml wash was collected as 4- to 500-,ul fractions in
1.5-ml microcentrifuge tubes. After the addition of 10 ,ug of
carrier DNA (pBR322), 400 ,ul of isopropanol was added to
each tube, and the tubes were immediately centrifuged at top
speed in an Eppendorf microcentrifuge for 30 min. (The
addition of carrier DNA to the sample prior to loading it on
the AX-20 column is unnecessary, since it does not improve
recovery of the sample from the column.) Pelleted samples
were washed once with 70% EtOH and once with 95% EtOH
and then dried in vacuo. With this procedure, >80% of total
viral RNA is recovered. To isolate tightly associated tRNA,
total viral RNA was heated for 3 min at 65°C in dissociation
buffer (20 mM Tris [pH 7.5], 200 mM NaCl, 2 mM disodium
EDTA), which will cause the release of loosely associated
tRNA from the genomic RNA. After quick cooling on ice,
the RNA sample was fractionated with an AX-20 column,
isopropanol precipitated in the presence of 10 ,ug of carrier
DNA, washed, and dried as described above. The 0.8 M KCl
buffer will elute the freed loosely associated tRNA along
with the initially free RNA, while the 1.3 M KCl buffer will
elute the genomic RNA along with the tRNA still tightly
associated with it.
Purification of human tRNAI 8 and tRNAL'3. Ten to 20 mg
of total tRNA can be isolated from 200 g of human placenta
by using the method of Roe (32), which uses standard
phenol-chloroform extractions to isolate total RNA, fol-
lowed by DEAE-cellulose chromatography to isolate total
tRNA. The tRNA was aminoacylated with [3H]lysine, and
tRNALYS fractions were isolated by using standard chro-
matographic methods for tRNA purification (sequentially,
DEAE-Sephadex A-50, reverse-phase chromatography [RPC-
5], and Porex C4 chromatography [8, 29]). A final purifica-
tion step used two-dimensional (2D) polyacrylamide gel
electrophoresis (PAGE) as described below. The Porex C4
tRNA'Y' fraction was resolved into two lysine tRNAs, while
the Porex C4 tRNALYS fraction remained a single species
during electrophoresis. The tRNALYs isoacceptor spots were
eluted from gel slices by soaking in water overnight and were
concentrated by ethanol precipitation. Their identity as
lysine tRNAs was confirmed through partial RNA sequenc-
ing (see below) and hybridization with DNA probes specific
for tRNALys.
In this report, we refer to two tRNA species representing
tRNALYs. The term tRNALYs refers to a population of two
tRNALYS species which differ by one base pair in the anti-
codon stem (29). The first major peak eluting from RPC-5
contains these two tRNA species, and these are not resolved
by Porex C4 chromatography. We do, however, resolve this
population into two tRNALYS species by the final step of 2D
PAGE. Since we have not determined which spot is tRNA~1Ys
and which is tRNALYS, we call both spots tRNA'S.
RNA labeling. The fractionated RNA samples were la-
beled by the [32P]pCp 3'-end-labeling technique (4). [32P]pCp
was made as follows. Five microcuries of [y-32P]ATP (spe-
cific activity, 3,000 Ci/mmol; Dupont Canada) was dried
down in a microcentrifuge tube, using N2. Then 100 ,lI of
reaction solution (50 mM Tris-HCl [pH 9.2], 5 mM MgCl2, 3
mM dithiothreitol, 5% bovine serum albumin, 1 FiM 3'-CMP,
10 U of T4 kinase) was added. The reaction mixture was
incubated at 37°C for 3 h, and the conversion of 3'-CMP
to [32P]pCp was monitored by polyethyleneimine thin-layer
chromatography in 0.8 M NH2SO4, which separates [32P]
pCp from [3 P]ATP.
Labeling of RNA with [32P]pCp was done as previously
described (4, 19). Free viral tRNA was labeled without
further treatment. Total associated tRNA was first heated to
65°C for 3 min, quickly cooled, and then labeled. Labeled
tightly associated tRNA was obtained by fractionating a
similar amount of labeled, total associated tRNA on an
AX-20 column as described above. After labeling of the
various RNA fractions, free [32P]pCp was removed from the
labeled macromolecules either by using Sephadex G-50
(Pharmacia) homemade spin columns, equilibrated with TE
buffer (10 mM Tris [pH 7.5], 1 mM EDTA), or during the
electrophoresis run. Before analysis by PAGE, the samples
were heated at 90°C for 2 min.
RNase T1 fingerprinting and RNA sequencing. Partial
RNase T1 digests are analyzed by using 1D PAGE to
separate the RNA fragments (25). To sequence the nucle-
otides at the 3' end of the tRNA molecule, the enzymatic
sequencing methodology was used. This method, first devel-
oped by Donis-Keller et al. (7) and reviewed in reference 22,
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uses enzymes which cut 3'- or 5'-end-labeled RNA at
specific bases. The radioactive fragments are separated by
1D PAGE, and the sequence is read from the electrophoretic
band pattern in a manner analogous to reading DNA se-
quencing gels. Specific enzymatic cleavage is altered in the
presence of modified bases, and other methodologies are
required to identify them. However, modified bases are
normally missing within the 18-nucleotide region at the 3'
end of tRNAs, and this method can result in the rapid
identification of tRNAs.
1D and 2D PAGE. Electrophoresis of viral RNA was
carried out at 4°C in a the Hoefer SE620 gel electrophoresis
apparatus. Gel size was 14 by 32 cm. The first dimension was
run in a 10% polyacrylamide-7 M urea gel for approximately
16 h at 800 V, until the bromophenol blue dye was beginning
to elute from the bottom of the gel. After autoradiography,
the piece of gel containing RNA was cut out, embedded in a
second gel (20% polyacrylamide-7 M urea), run for 46 h
(25-W limiting), and then subjected to autoradiography. All
electrophoretic runs were carried out in 0.5 x TBE (1x TBE
is 5 mM Tris, 5 mM boric acid, and 1 mM disodium EDTA).
The electrophoretic gel patterns presented in this report
show only low-molecular-weight RNA, since the high-mo-
lecular-weight viral genomic RNA cannot enter the poly-
acrylamide gels. Furthermore, these patterns represent only
the most abundant tRNA species present, since the high
specific activities of the labeled tRNAs used will reveal
many more minor-abundance species with longer film expo-
sures.
The amount of 32P radioactivity in each major-abundance
tRNA relative to other tRNA-sized species seen in the 2D
PAGE was determined either by excising each spot from the
gel and directly counting its radioactivity in a liquid scintil-
lation counter, using Cerenkov counting, or by analyzing the
2D PAGE tRNA pattern via phosphor imaging (Bio-Rad,
Toronto, Ontario, Canada). The two methods gave similar
results.
Detection of tRNALYS isoacceptors by RNA-DNA hybridiza-
tion. To detect the presence of tRNAY'S and tRNA3'YS in
viral RNA, we have synthesized 18-mer DNA oligonucleo-
tides complementary to the 3' 18 nucleotides of tRNA'S
(5'-TGGCGCCCAACGTGGGGC-3') or tRNA'YS (5'-TGGC
GCCCGAACAGGGAC-3'). These DNA probes hybridize
specifically with tRNAY's or tRNA3YS (see Fig. 7A) and
were hybridized to dot blots of RNA samples on Hybond N
(Amersham). The DNA oligomers were 5' end labeled with
T4 polynucleotide kinase and [-y-32P]ATP (3,000 Ci/mmol;
Dupont Canada), and specific activities of 108 to 109 cpm/,Lg
were generally reached. Approximately 107 cpm per oli-
gomer was generally used per blot in hybridization reactions.
RESULTS
Figure 1A shows the 2D PAGE pattern of tRNA incorpo-
rated into HIV-1 transiently produced in transfected COS-7
cells, and Fig. 2A shows the tRNA species incorporated into
the mutant virions produced in Vero cells established with
pMT-HIV-1. COS-7 cell-produced virus contain four major-
abundance tRNA species, spots 1, 2, and 4 being most
abundant. Figure 1B shows that in 1D PAGE, species 1 and
2 have electrophoretic mobilities similar to those of the two
lysine tRNAs that we have isolated from the tRNALys
isoacceptor family, while species 3 and 4 have mobilities
similar to that of purified tRNALYS. Species 1 to 4 isolated
from the mutant virus present a pattern similar to that of the
wild-type viral tRNAs in 2D PAGE (Fig. 2A) and migrate in
A
20%L
10%
3 2
B
201
A B C 1 2 3 4
FIG. 1. tRNA incorporated into HIV-1 produced in transfected
COS-7 cells. (A) 2D PAGE (performed as described in the text) of free
viral tRNA; (B) comparison of electrophoretic mobilities of pure
human tRNAjL3s and tRNA3LYS with that of HIV-1 tRNA species foundin the free tRNA population. Lanes A to C represent purified human
placental tRNA'3YS and the two components of tRNAlL, respectively;
lanes 1 to 4 correspond to the like-numbered spots in panel A.
1D PAGE with mobilities similar to those of their like-
numbered counterparts in wild-type virus (Fig. 2B). How-
ever, the mutant virus contains an additional five RNA
species not seen in the COS-7 cell-produced HIV-1.
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FIG. 2. tRNA incorporated into the mutant HIV-1 produced in
chronically infected Vero cells. (A) 2D PAGE (performed as de-
scribed in the text) of free viral tRNA; (B) comparison of electro-
phoretic mobilities of pure human tRNALY' and tRNA3YS with
HIV-1 tRNA species found in the free tRNA population. Lanes A to
and C represent purified human placental tRNA3LYS and the two
components of tRNA,S, respectively; lanes 1 to 9 correspond to the
like-numbered spots in panel A.
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FIG. 3. 1D PAGE of partial RNase T1 digests of human placental
tRNALYS and free tRNAs incorporated into HIV-1 produced in
transfected COS-7 cells. Lanes: A to C, human tRNA3LYS and the
two human tRNA species resolved from the tRNALys fraction,
respectively; 1 to 4, the free viral tRNA species, numbered accord-
ing to the system used to label the individual tRNA spots shown in
Fig. 1A.
The fingerprints of partial T1 digests of purified human
tRNALYS isoacceptors and viral tRNAs isolated from COS-7
cell-produced HIV-1 were compared (Fig. 3). It is clear that
spots 1 and 2 produce the same fingerprint pattern as does
tRNAiLYs, while spot 4 (but not spot 3) produces the same
fingerprint pattern as does tRNA yS.
Figure 4 shows similar T1 digest fingerprints for the RNA
species present in the mutant virus. The T1 digest finger-
prints of species 1 to 4 of the mutant virus are identical to
those of tRNAs 1 to 4 found in the wild-type virus. The
identity of these mutant viral RNA species is further con-
firmed in Fig. 5, which shows 1D PAGE RNA sequencing
gels of spots 1, 2, and 4. The sequences of the last 18
nucleotides of the 3' ends of these viral tRNAs again indicate
that spots 1 and 2 are tRNALYS and spot 4 is tRNA3LYS (29).
The partial sequences of the 3' termini of all nine RNA
species found in the mutant virus are listed in Table 1. Spot
3, found in both wild-type and mutant viruses, appears to be
a tRNAI'le isoacceptor, while the sequences of spots 8 and 9
match that of mammalian tRNAHIS. We have not been able
to match the partial sequences of spots 5 to 7 with any
known RNA listed in the current data bases.
The tRNA incorporated into wild-type HIV-1 contains
FIG. 4. 1D PAGE of partial RNase T1 digests of human placental
tRNALYS and free tRNAs incorporated into mutant HIV-1 produced
in chronically infected Vero cells. Lanes: OH-, alkaline hydrolysis
of tRNAlL,s with base; A to C, human tRNA3LYS and the two human
tRNA species resolved from the tRNAL3S fraction, respectively; 1 to9, the free viral tRNA species, numbered according to the system
used to label the individual tRNA spots shown in Fig. 2A. Because
of the weak signal of placental tRNA3LYS in panel II, another
fingerprint of this tRNA is shown in panel I.
three, and possibly four, major-abundance species (with the
three tRNALYs isoacceptors being the most abundant). Sim-
ple tRNA patterns of incorporation have also been found for
mouse mammary tumor virus (27) and in avian myeloblasto-
sis virus and Rous sarcoma virus as well (20). In all retrovi-
ruses examined, including HIV-1, there are also more minor-
abundance species whose appearance is dependent upon film
exposure. In HIV-1, their amount relative to the tRNALYS
isoacceptors also varies from one viral preparation to an-
other. Analysis of the electrophoretic patterns of free tRNA
in wild-type HIV-1 reveals that, on average, the radioactiv-
ity in the four major-abundance species represents 80% of
the total radioactivity on the gel. Among the four major
tRNA species, the relative abundances are as follows: spot 1
(tRNALys), 46%; spot 2 (tRNALYs), 16%; spot 3 (tRNAI1e),
8%; and spot 4 (tRNA Ys), 30%. The 2:1 ratio of tRNALys to
tRNALYs is similar to the concentration ratio of these tRNAs
in the cell.
The primer tRNA for reverse transcription in HIV-1 is
believed to be tRNA3LYS. In other retroviruses examined, the
primer tRNA is distinguished from other viral tRNAs by
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FIG. 5. RNA sequence gels showing the partial nucleotide sequences at the 3' termini of human placental tRNA3LYS (A), mutant viral spot
4 (B), human placental tRNAlL,s (C), and mutant viral spot 1 (D). Lanes: OH-, alkaline hydrolysis; Ti, U2, PhyM, and B.c., RNases used
for enzymatic sequencing (T1, U2, PhyM, and Bacillus cereus, respectively).
being found tightly associated with the viral RNA genome.
Figure 6 shows 1D PAGE of tightly associated tRNA iso-
lated from COS-7 cell-produced HIV-1. A single tRNA-sized
species which moves with the electrophoretic mobility of
tRNA3y' is found, supporting the premise that this tRNA is
the primer. This tRNA also hybridizes with a tRNA"-Ys-
specific probe. We have developed 18-mer DNA probes
which specifically hybridize with either tRNA,Ys or
tRNA3YS. These probes are complementary to the last 18
nucleotides at the 3' ends of these tRNAs. The tRNA dot
blots in Fig. 7A demonstrate that these probes hybridize
only to their respective tRNALYS isoacceptors and to the
tRNALYS-rich fraction obtained during the purification of
human placental tRNALYS by DEAE-cellulose chromatogra-
phy. These oligomer probes also do not hybridize to the
tRNALYs-poor fraction from the DEAE-cellulose column or
to Escherichia coli tRNAPhe, which shows a 67% homology
to tRNALys in the last 3' 18 nucleotides. Using these probes,
we find (Fig. 7B) that the free tRNA populations of both
wild-type and mutant HIV-1 contain tRNA1,2s and tRNALYS.
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TABLE 1. Sequences of 3' termini of low-molecular-weight
viral RNAs
Spot Sequence (3'-5') Identity
1 ACCGCGGGUUGCACCCCG tRNA1,22 ACCGCGGGUUGCACCCCG tRNA1s
3 ACCACCGGGCAUGCCCCU tRNA'G
4 ACCGCGGGCUUGUCCCUG tRNA3LYs
5 ACCGCGGGGUGGUGACUG ?
6 ACCACGGAUACAGGUCUU ?
7 ACCGCAAGGGACUAAACG ?
8 ACCACGGCACUGAGCCUA tRNAHiS
9 ACCACGGCACUGAGCCUA tRNAHiS
The tightly associated tRNA from COS-7 cell-produced
HIV-1 hybridizes only with the tRNALY'-specific probe,
while neither tRNALYS isoacceptor is detected in the tightly
associated fraction isolated from similar amounts of mutant
virus.
Figure 6 shows that in addition to tRNALYS, a larger RNA
species is found tightly associated with the viral genome. We
have previously reported the presence of this RNA in the
tightly associated fraction of RNAs isolated from HIV-1
produced from chronically infected H9 cells. It has an
approximate size of 185 nucleotides (18). We also find this
RNA species in mouse mammary tumor virus (19) but do not
find it in the mutant virus RNA reported here. The identity of
this RNA is unknown. In addition to this 7S-sized RNA,
HIV-1 low-molecular-weight RNA contains a discrete RNA
migrating as a 5S RNA, i.e., approximately 124 bp in size
(18). Both 5S and 7S RNAs have also been found in avian
retrovirus (35, 39).
DISCUSSION
In retroviruses, tRNAs are found both in a free population
and in a subfraction associated with the genomic RNA,
which can be further fractionated into loosely and tightly
associated tRNA (39). In this report, we have characterized
the free and tightly associated tRNA populations found in
infectious, wild-type HIV-1 and in a noninfectious mutant
HIV-1 particle which lacks both long terminal repeats and
10% *
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FIG. 6. 1D PAGE of tightly associated tRNA found in HIV-1
produced in COS-7 cells (lane 1) and purified human tRNA'YS (lane
2).
*8 vp
9
FIG. 7. Hybridization of RNA dot blots with DNA probes spe-
cific for tRNALYS (A) and tRNA3LYS (B). Rows 1 to 5 contain 100 ng
of purified or partially purified tRNAs and are used to demonstrate
the specificity of the two DNA probes; rows 6 to 9 contain viral
RNA samples. Rows: 1, tRNALYs; 2, tRNA3Ys; 3 and 4, tRNALYs-
poor and tRNALYs-rich fractions, respectively, from the DEAE-
Sephadex A-SO chromatography used in the purifications of the
placental tRNALYS isoacceptors; 5, E. coli tRNAPhC; 6 and 7, free
and tightly associated tRNA, respectively, from HIV-1 produced in
COS-7 cells; 8 and 9, free and tightly associated tRNA, respectively,
from mutant HIV-1-like particles produced in Vero cells.
the primer binding site in the proviral DNA genome. (The
loosely associated fraction was not characterized in this
work.) Primer tRNA is found in the free fraction and has also
been found to be more tightly associated with the RNA
genome than are other viral tRNAs (11, 26, 27, 38, 40). In
these studies, we have found that the free tRNA populations
of both wild-type and mutant HIV-1 contain two species of
tRNALys, tRNALYS, and tRNAIIC. tRNALYS is the putative
primer for reverse transcription; in support of this hypothe-
sis, we have found that the COS-7 cell-produced virus
contains a tRNA tightly associated with the viral genome
which migrates with the same electrophoretic mobility as
does tRNALYS and hybridizes to a tRNALYS-specific DNA
probe. The mutant virus does not contain this tightly asso-
ciated tRNA. Our data show that neither a different cell type
nor the absence of the primer binding site alters the select
incorporation of the tRNALYs isoacceptors. We conclude
that the primer binding site is not required for tRNALYS
incorporation, unless the mechanism for primer tRNA incor-
poration in Vero cells is different from that in COS-7 cells.
This seems unlikely, since our result supports previous work
which indicates that the RNA genome is not required for
primer tRNA incorporation in either murine leukemia virus
(23) or avian sarcoma virus (28).
The incorporation of the tRNALys isoacceptors into HIV-1
need not reflect a viral function that they perform but may
occur because the recognition signal for selecting primer
tRNA3LYS is shared with the other tRNALYS isoacceptors. Of
course, one cannot eliminate the possibility of a viral func-
tion for tRNAs present in more minor amounts in wild-type
virus. However, we feel that the variation that we observe in
the abundance, or even detectability, of some tRNA-sized
species present in HIV-1 produced in different cell types (18)
argues against their playing an essential role in the viral life
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cycle. Such variability is also demonstrated by the absence
of mutant spots 8 and 9 (tRNAHiS) and spots 5, 6, and 7
(unidentified) in the wild-type virus, and we therefore feel it
unlikely that the abundance of these species in the mutant
virus reflects a viral function.
tRNA3'YS is believed to be the primer tRNA for HIV-1 RT.
We have in fact found only one tRNA tightly associated to
the viral RNA genome in wild-type virus. It has the electro-
phoretic mobility of tRNALYS, and it hybridizes with a
tRNALYs-specific probe but not with a tRNALYs-specific
probe. This finding indicates that the two tRNA1S isoaccep-
tors incorporated into the virus probably do not also serve as
primer tRNA. Their incorporation along with tRNA'YS may
therefore reflect a recognition signal for incorporation shared
by all three species. This phenomenon is also observed in
mouse mammary tumor virus, a virus that uses tRNALYS as
a primer but also incorporates tRNALys as the only other
major tRNA species (27).
In considering what feature these tRNAs have in common
which allows for them to be selected for incorporation, one
must consider what process might be used to bring the
tRNAs into the virus. This mechanism is largely unknown,
but a candidate viral protein which may play a role in this
process is the p1609a9-Po precursor. This protein contains
the RT sequences, and the role of RT in select tRNA
incorporation has been reported. In mutant avian sarcoma
virus (28) and murine leukemia virus (24) lacking RT protein,
the incorporation of host cell tRNA becomes nonselective.
Mature HIV-1 RT (p66/pSi) has also been shown to interact
with tRNALYS in vitro (3). However, p1609'9-J°I rather than
mature RT is implicated in tRNA selection, since the pre-
cursor is not cleaved until after viral budding (6, 41). (The
p1609ag-Pol precursor is cleaved by a viral protease, and we
have recently observed that in a protease-negative mutant
HIV-1 which is unable to process these precursors, tRNALYS
is both incorporated into the virus and placed onto the viral
genome, indicating that these processes do not depend upon
precursor processing [17].)
It is unlikely that pl609&9-P°' would interact with naked
tRNA, since tRNA is found complexed in the cell with
proteins such as EF-lac and aminoacyl tRNA synthetases.
Therefore, a specific interaction between p1609a&PO' and
tRNALYS might involve an initial interaction with the protein
that the tRNAs are complexed with. If this protein is lysine
tRNALYS synthetase, the specificity of binding might result
from an initial protein-protein, rather than protein-tRNA,
interaction. This interaction could occur during p16099a-Po
synthesis, since all of these components would be in close
proximity around the translational apparatus. Further exper-
iments will be needed to determine whether p1609a9-Po
demonstrates specific interaction with either deproteinized
tRNALYS or tRNALYS-protein complexes.
The popularity of HIV-1 as an object of study has resulted
in the availability of a large number of well-characterized
mutant proviral DNAs. Through transfection, these DNAs
can be used to produce mutant virus in the COS cell system.
The ability to now measure both the incorporation and
genomic placement of primer tRNA3LYs in HIV-1 produced in
transfected COS cells will facilitate the elucidation of the
mechanism underlying these processes through a study of
the effects of different mutations on these processes.
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